Foundayo (Orforglipron)

Foundayo (orforglipron) is Eli Lilly's FDA-approved once-daily oral GLP-1 receptor agonist approved on April 1, 2026 — a landmark drug for a specific reason beyond its efficacy. Unlike the oral semaglutide pill (Wegovy oral, Rybelsus), orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. This chemical class distinction has a critical practical consequence: because it is not a peptide, it does not get degraded by digestive enzymes in the way that semaglutide does, and it does not require a complex absorption enhancer. As a result, Foundayo can be taken at any time of day, with or without food, and without water restrictions — a unique advantage over all other oral GLP-1 drugs currently approved. The Phase 3 ATTAIN clinical trial program evaluated orforglipron across multiple doses and populations. At the highest dose (36 mg once daily) over 72 weeks, participants achieved an average weight loss of 12.4% — approximately 27 pounds — with an estimated 60% of participants achieving at least 10% body weight reduction. While 12.4% is lower than the 16.6% achieved with oral semaglutide in OASIS 4, the no-food-restriction dosing protocol may make adherence meaningfully better in real-world settings, particularly for patients with demanding work schedules or irregular meal patterns. Orforglipron launched commercially on April 6, 2026, via LillyDirect, followed by broader pharmacy and telehealth distribution. Critically, Lilly priced it at $149 per month for self-pay patients — dramatically below every other GLP-1 on the market. Some commercially insured patients pay as little as $25 per month with Lilly's savings card. This pricing strategy represents a deliberate effort to expand GLP-1 access well beyond the well-insured populations that have predominantly used Wegovy and Zepbound. Orforglipron does not yet carry a cardiovascular indication; outcomes trials are underway.